Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

Pediatric Blood and Cancer

Volumn 52, Issue 3, 2009, Pages 357-363

  Veltroni, Marinella ^a,b   Sainati, Laura ^a,h   Zecca, Marco ^c   Fenu, Susanna ^d   Tridello, Gloria ^a   Testi, Anna Maria ^e   Merlone, Alessandra Di Cesare ^c   Buldini, Barbara ^a   Leszl, Anna ^a   Nigro, Luca Lo ^f   Longoni, Daniela ^g   Bernini, Gabriella ^b   Basso, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h Division of Haematology and Oncology   (Italy)

Author keywords

Acute myeloid leukemia; CD7; Flow cytometry; Immunophenotype; Pediatric myelodysplastic syndromes

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CD7 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW; CONTROL GROUP; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MATURATION; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; ADOLESCENT; BLAST CELL CRISIS; CANCER STAGING; CELL DIFFERENTIATION; CHILD; CYTOLOGY; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ANTIGENS, CD34; ANTIGENS, CD7; BLAST CRISIS; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PRECURSOR CELLS, B-LYMPHOID; PROGNOSIS; SURVIVAL RATE;

EID: 58949093280     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21874     Document Type: Article

References (42)

1. Heaney ML, Golde D. Myelodysplasia. N Engl J Med 1999;21: 1649-1660.
2. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: Incidence and predisposing conditions. Leukemia 1995;9:1569-1572.
3. Hasle H, Wadsworth LD, Massing BG, et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999;106:1027-1032.
4. Webb DKH, Passmore SJ, Hann IM, et al. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol 2002;117:33-39.
5. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelo-monocytic leukemia or myelodysplastic syndrome: A report from the Children's Cancer Group. J Clin Oncol 2002;20:434-440.
6. Niemeyer CM, Duffner U, Bender-Götze C, et al. AML-Type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood 2000;96:521a.
7. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: A study of 68 children and a new prognostic scoring system. Blood 1995;85:1742-1750.
8. Hasle H, Niemeyer CM, Chessells GM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-282.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
10. Cantú Rajnoldi A, Fenu S, Kerndrup G, et al. For the European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Ann Hematol 2005;84:429-433.
11. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998;83:1104-1115.
12. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98:979-987.
13. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100:3887-3896.
14. Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100:2349-2356.
15. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in Myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403.
16. Del Canizo MC, Fernandez ME, Lopez A, et al. Immunopheno- typic analysis of myelodysplastic syndromes. Haematologica 2003;88:402-407.
17. Benesch M, Deeg HJ, Wells D, et al. Flow cytometry for diagnosis and assessment of prognosis in patients with Myelodysplastic syndromes. Hematology 2004;9:171-177.
18. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005;124:170-181.
19. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with Myelodysplastic syndrome. Leukemia 2005;19:776-783.
20. Ogata K, Yoshida Y. Clinical implications of blast immunopheno- types in myelodysplastic syndromes. Leuk Lymphoma 2005;46: 1269-1274.
21. Tavil B, Cetin M, Tuncer M. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res 2006;30:222-224.
22. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006;125:884-894.
23. Loken MR, van de Loosdrecht A, Ogata K, et al. Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 2008;32:5-17.
24. Van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111:1067-1077.
25. Ogata K, Kishikawa Y, Satoh C, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006;108:1037-1044.
26. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B- cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005;106:2982-2991.
27. Ribeiro E, Matarraz-Sudon S, de Santiago M, et al. Maturation- associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leuk Res 2006; 30:9-16.
28. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007;31:727-736.
29. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
30. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: High frequency of lymphoid antigen expression and comparison ofimmunophenotype, French- American-British classification, and karyotypic abnormalities. Am J Clin Pathol 1998;109:211-222.
31. Basso G, Buldini B, De Zen L, et al. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86:675-692.
32. De Zen L, Orfao A, Cazzaniga G, et al. Quantitative multi- parametric immunophenotyping in acute lymphoblastic leukemia: Correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000;14:1225-1231.
33. ISCN 2005. Shaffer LG, Tommerup N, editors. An international system for human cytogenetic nomenclature (2005). Basel: Karger; 2005.
34. Agresti A, editor. 1990. Categorical data analysis. New York, NY: Wiley & Sons.
35. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. Chichester: John Wiley & Sons; 1995.
36. Font P, Subira D, Mtnez-Chamorro C, et al. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leuk Res 2006;30:957-963.
37. Font P, Subira D. Expression of CD7 in myelodysplastic syndromes (MDS): Is this a truly prognostic factor? Leuk Res 2008;32:185-186.
38. McKenna RW, Washington LT, Equino DB, et al. Immunopheno- typic analysis of haematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow-cytometry. Blood 2001;98:2498-2507.
39. Steizer GT, Goodpasture L. Use of multiparametric flow cytometry and immunophenotyping for the diagnosis and classification of acute myeloid leukaemia. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. New York, NY: Wiley-Liss Press. 2000; pp. 215-239.
40. Lo Coco F, De Rossi G, Pasqualetti F, et al. CD7 positive acute myeloid leukaemia: A subtype associated with cell immaturity. Br J Hematol 1989;73:480-485.
41. Ogata K, Yokose N, Shioi Y, et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001;115:612-615.
42. Del Poeta G, Stasi R, Venditti A, et al. CD7 expression in acute myeloid leukemia. Leuk Lymphoma 1995;17:111-119.